The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma

Daniel E. Abbott, Ching Wei David Tzeng, Ryan P. Merkow, Scott B. Cantor, George J. Chang, Matthew Harold Katz, David J. Bentrem, Karl Y. Bilimoria, Christopher H. Crane, Gauri R. Varadhachary, James L. Abbruzzese, Robert A. Wolff, Jeffrey E. Lee, Douglas B. Evans, Jason B. Fleming

Research output: Contribution to journalArticle

48 Scopus citations

Abstract

Background. In treating pancreatic cancer, there is no clearly defined optimal sequence of chemotherapy, radiation therapy and surgery. Therefore, cost-effectiveness should be considered. The objective of this study was to compare cost and outcomes between a surgery-first approach versus neoadjuvant chemoradiation followed by surgery for resectable pancreatic head cancer. Methods. A decision analytic model was constructed to compare the 2 approaches. Data from the National Cancer Database, National Surgical Quality Improvement Program, and literature populated the surgery-first arm. Data from our prospectively maintained institutional pancreatic cancer database populated the neoadjuvant arm. Costs were estimated by Medicare payment (2011 U.S. dollars). Survival was reported in quality-adjusted life-months (QALMs). Results. The neoadjuvant chemoradiation arm consisted of 164 patients who completed preoperative therapy. Of these, 36 (22 %) did not proceed to surgery; 12 (7 %) underwent laparotomy but had unresectable disease; and 116 (71 %) underwent definitive resection. The surgeryfirst pproach cost $46,830 and yielded survival of 8.7 QALMs; the neoadjuvant chemoradiation approach cost $36,583 and yielded survival of 18.8 QALMs. In the neoadjuvant arm, costs and survival times for patients not undergoing surgery, those with unresectable disease at laparotomy, and those completing surgery were $12,401 and 7.7 QALMs, $20,380 and 7.1 QALMs, and $45,673 and 23.4 QALMs, respectively. Conclusions. Neoadjuvant chemoradiation for pancreatic cancer identifies patients with early metastases or poor performance status, who can be spared an ineffective or prohibitively morbid operation, and is associated with improved survival at significantly lower cost than a surgery- first approach. Neoadjuvant chemoradiation followed by surgery is a strategy that provides more cost-effective care than a surgery-first approach.

Original languageEnglish (US)
JournalAnnals of surgical oncology
Volume20
Issue number3 SUPPL.
DOIs
StatePublished - Feb 11 2013

ASJC Scopus subject areas

  • Surgery
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma'. Together they form a unique fingerprint.

  • Cite this

    Abbott, D. E., Tzeng, C. W. D., Merkow, R. P., Cantor, S. B., Chang, G. J., Katz, M. H., Bentrem, D. J., Bilimoria, K. Y., Crane, C. H., Varadhachary, G. R., Abbruzzese, J. L., Wolff, R. A., Lee, J. E., Evans, D. B., & Fleming, J. B. (2013). The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Annals of surgical oncology, 20(3 SUPPL.). https://doi.org/10.1245/s10434-013-2882-0